Elucidating the Differential Mechanisms of Jingui Shenqi Pill and Mingmu Dihuang Pill in the Treatment of Diabetic Nephropathy Based on Yin-Yang Theory.

IF 4.7 2区医学 Q1 CHEMISTRY, MEDICINAL

Drug Design, Development and Therapy Pub Date : 2025-04-10 eCollection Date: 2025-01-01 DOI:10.2147/DDDT.S517143

Shijie Bi, Zhenzhen Xu, Anlei Yuan, Zewen Wang, Yanxia Liu, Bin Yu, Jiaye Tian, Chaoqun Liu, Liansheng Qiao, Zhibin Wang, Yanling Zhang

{"title":"Elucidating the Differential Mechanisms of Jingui Shenqi Pill and Mingmu Dihuang Pill in the Treatment of Diabetic Nephropathy Based on Yin-Yang Theory.","authors":"Shijie Bi, Zhenzhen Xu, Anlei Yuan, Zewen Wang, Yanxia Liu, Bin Yu, Jiaye Tian, Chaoqun Liu, Liansheng Qiao, Zhibin Wang, Yanling Zhang","doi":"10.2147/DDDT.S517143","DOIUrl":null,"url":null,"abstract":"Background: The Yin-Yang attributes of MMDH and JGSQ in treating diabetic nephropathy (DN) remain unexplored.Methods: UPLC-MS identified formula components, network pharmacology analyzed common DN targets, and in vitro renal fibrosis models assessed efficacy. Transcriptomics revealed key pathways, and molecular docking simulated component-target interactions.Results: UPLC-MS confirmed the compositional complexity of MMDH and JGSQ. Network pharmacology indicated their involvement in multiple DN-related pathways. In vitro, JGSQ alleviated fibrosis and enhanced adhesion via FN and E-cad, while MMDH reduced interstitial fibrosis via FN and VIM. Transcriptomics showed JGSQ regulates the TGF-β pathway, and MMDH modulates the TNF pathway. Molecular docking confirmed key components binding to TGFB1 and TNFA.Conclusion: MMDH and JGSQ exhibit distinct chemical compositions, targets, and pathways, underscoring their Yin-Yang regulatory roles in kidney function.","PeriodicalId":11290,"journal":{"name":"Drug Design, Development and Therapy","volume":"19 ","pages":"2817-2831"},"PeriodicalIF":4.7000,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11998986/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Design, Development and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/DDDT.S517143","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The Yin-Yang attributes of MMDH and JGSQ in treating diabetic nephropathy (DN) remain unexplored.

Methods: UPLC-MS identified formula components, network pharmacology analyzed common DN targets, and in vitro renal fibrosis models assessed efficacy. Transcriptomics revealed key pathways, and molecular docking simulated component-target interactions.

Results: UPLC-MS confirmed the compositional complexity of MMDH and JGSQ. Network pharmacology indicated their involvement in multiple DN-related pathways. In vitro, JGSQ alleviated fibrosis and enhanced adhesion via FN and E-cad, while MMDH reduced interstitial fibrosis via FN and VIM. Transcriptomics showed JGSQ regulates the TGF-β pathway, and MMDH modulates the TNF pathway. Molecular docking confirmed key components binding to TGFB1 and TNFA.

Conclusion: MMDH and JGSQ exhibit distinct chemical compositions, targets, and pathways, underscoring their Yin-Yang regulatory roles in kidney function.

查看原文本刊更多论文

基于阴阳理论探讨金桂参芪丸与明目地黄丸治疗糖尿病肾病的差异机制。

背景：MMDH和JGSQ治疗糖尿病肾病（DN）的阴阳属性尚不清楚。方法：UPLC-MS鉴定配方成分，网络药理学分析常见DN靶点，体外肾纤维化模型评估疗效。转录组学揭示了关键途径，分子对接模拟了组分-靶标相互作用。结果：UPLC-MS证实了MMDH和JGSQ的组成复杂性。网络药理学表明它们参与多种dn相关通路。体外，JGSQ通过FN和E-cad减轻纤维化，增强粘附，而MMDH通过FN和VIM减轻间质纤维化。转录组学显示JGSQ调节TGF-β通路，MMDH调节TNF通路。分子对接确认了与TGFB1和TNFA结合的关键成分。结论：MMDH和JGSQ具有不同的化学成分、作用靶点和途径，强调了它们在肾功能中的阴阳调节作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drug Design, Development and Therapy CHEMISTRY, MEDICINAL-PHARMACOLOGY & PHARMACY

CiteScore

9.00

自引率

0.00%

发文量

382

审稿时长

>12 weeks

期刊介绍： Drug Design, Development and Therapy is an international, peer-reviewed, open access journal that spans the spectrum of drug design, discovery and development through to clinical applications. The journal is characterized by the rapid reporting of high-quality original research, reviews, expert opinions, commentary and clinical studies in all therapeutic areas. Specific topics covered by the journal include: Drug target identification and validation Phenotypic screening and target deconvolution Biochemical analyses of drug targets and their pathways New methods or relevant applications in molecular/drug design and computer-aided drug discovery* Design, synthesis, and biological evaluation of novel biologically active compounds (including diagnostics or chemical probes) Structural or molecular biological studies elucidating molecular recognition processes Fragment-based drug discovery Pharmaceutical/red biotechnology Isolation, structural characterization, (bio)synthesis, bioengineering and pharmacological evaluation of natural products** Distribution, pharmacokinetics and metabolic transformations of drugs or biologically active compounds in drug development Drug delivery and formulation (design and characterization of dosage forms, release mechanisms and in vivo testing) Preclinical development studies Translational animal models Mechanisms of action and signalling pathways Toxicology Gene therapy, cell therapy and immunotherapy Personalized medicine and pharmacogenomics Clinical drug evaluation Patient safety and sustained use of medicines.